{
    "info": {
        "nct_id": "NCT06218303",
        "official_title": "A Clinical Study of a Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma in Situ",
        "inclusion_criteria": "1. Postmenopausal female, 18 years of age or older (no menstrual period for at least 12 months, biochemical menopausal by FSH/LH or S/P oophorectomy)\n2. Capable of providing informed consent and willing to comply with study procedures\n3. Biopsy-proven ER+ DCIS\n\n   * The signed pathology report from the attending pathologist will be used to determine eligibility\n   * Sufficient amount of DCIS remaining in the diagnostic core biopsy block(s) and available for research\n   * Patients with DCIS suspicious for microinvasion on core biopsy will be eligible because many of these patients will not have invasion on final pathology\n   * Women presenting with concurrent bilateral DCIS are eligible only if both the right and left DCIS lesions are ER+, and tissue from both sides will be analyzed and must meet the criteria below\n4. DCIS must be ≥ 1cm based on the extent of calcifications on mammogram, the presence of a mass on ultrasound or enhancement on MRI OR DCIS ≥ 5mm on one single core by pathologic evaluation OR DCIS < 5mm if identified in ≥ 2 cores\n5. Candidate for aromatase inhibitor\n6. Surgery planned as part of definitive local therapy\n7. ECOG PS 0-1\n8. Absolute neutrophil count ≥ 1.5 x 109/L\n9. Platelet count ≥ 100 x 109/L\n10. Hemoglobin ≥ 9 g/dl or ≥ 5.6 mmol/L\n11. Creatinine ≤ 1.5X the upper limit of normal OR creatinine clearance ≥ 60 ml/min\n12. Total bilirubin ≤ 1.5X the ULN; ≤ 2x ULN for patients with Gilbert's disease\n13. AST and ALT ≤ 2.5X ULN\n14. INR/PT/aPTT ≤ 1.5X ULN or within the therapeutic range if on anti-coagulation\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Invasive breast cancer > 1mm on pathologic evaluation\n2. Second malignancy within the last 5 years (definitively treated superficial non-melanoma skin cancer, melanoma in situ, cervical carcinoma in situ allowed)\n3. Current hormone replacement therapy, selective estrogen receptor modulator therapy, or aromatase inhibitor therapy--if yes, wash out of 30 days must occur prior to baseline biopsy for the study\n4. Recurrent ipsilateral DCIS\n5. Current steroid therapy (doses for physiologic replacement in adrenal dysfunction or for contrast allergy pre-medication for contrast allergy or similar indication allowed, topical, ocular and intranasal steroids allowed)\n6. Current Immunomodulator therapy (includes anti-CD20 antibodies)\n7. History of autoimmune disease requiring systemic immunosuppression, or active autoimmune disease. Replacement therapy with thyroxine, insulin, and physiologic corticosteroids for adrenal or pituitary insufficiency is acceptable.\n8. History of immune deficiency\n9. Active infection requiring systemic therapy\n10. Any medical or psychiatric condition, substance abuse disorder, medical therapy, or laboratory abnormality that might interfere with the patient's participation for the full duration of the study or compliance with the requirements of the study\n11. Known active hepatitis B (hepatitis B surface antigen-reactive) or hepatitis C (hepatitis C virus RNA positive). Patients who are hepatitis B core antibody positive without hepatitis B surface antigen reactivity are eligible. Patients who have antibody for hepatitis C are eligible only if hepatitis C RNA is negative by PCR.\n12. Known history of HIV (presence of HIV antibodies for HIV 1 and HIV 2)\n13. Received a live vaccine within 30 days of the first dose of treatment\n14. History of allergies to any component of the MUC1 vaccine or HiltonolR adjuvant\n15. Participation on any investigational vaccine, drug, or device trial within the last 30 days",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "1. Postmenopausal female, 18 years of age or older (no menstrual period for at least 12 months, biochemical menopausal by FSH/LH or S/P oophorectomy)",
            "criterions": [
                {
                    "exact_snippets": "Postmenopausal female ... no menstrual period for at least 12 months, biochemical menopausal by FSH/LH or S/P oophorectomy",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        },
                        {
                            "requirement_type": "definition",
                            "expected_value": [
                                "no menstrual period for at least 12 months",
                                "biochemical menopausal by FSH/LH",
                                "S/P oophorectomy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "18 years of age or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The signed pathology report from the attending pathologist will be used to determine eligibility",
            "criterions": [
                {
                    "exact_snippets": "The signed pathology report from the attending pathologist will be used to determine eligibility",
                    "criterion": "pathology report",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "attending pathologist"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with DCIS suspicious for microinvasion on core biopsy will be eligible because many of these patients will not have invasion on final pathology",
            "criterions": [
                {
                    "exact_snippets": "Patients with DCIS suspicious for microinvasion on core biopsy will be eligible",
                    "criterion": "DCIS suspicious for microinvasion on core biopsy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Candidate for aromatase inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Candidate for aromatase inhibitor",
                    "criterion": "aromatase inhibitor candidacy",
                    "requirements": [
                        {
                            "requirement_type": "candidacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Platelet count ≥ 100 x 109/L",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 100 x 109/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sufficient amount of DCIS remaining in the diagnostic core biopsy block(s) and available for research",
            "criterions": [
                {
                    "exact_snippets": "Sufficient amount of DCIS remaining in the diagnostic core biopsy block(s) and available for research",
                    "criterion": "DCIS in diagnostic core biopsy block(s)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "sufficient amount"
                        },
                        {
                            "requirement_type": "availability for research",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Absolute neutrophil count ≥ 1.5 x 109/L",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count ≥ 1.5 x 109/L",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Hemoglobin ≥ 9 g/dl or ≥ 5.6 mmol/L",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 9 g/dl or ≥ 5.6 mmol/L",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 9,
                                        "unit": "g/dl"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5.6,
                                        "unit": "mmol/L"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. ECOG PS 0-1",
            "criterions": [
                {
                    "exact_snippets": "ECOG PS 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Creatinine ≤ 1.5X the upper limit of normal OR creatinine clearance ≥ 60 ml/min",
            "criterions": [
                {
                    "exact_snippets": "Creatinine ≤ 1.5X the upper limit of normal",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "X ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "creatinine clearance ≥ 60 ml/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "ml/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Capable of providing informed consent and willing to comply with study procedures",
            "criterions": [
                {
                    "exact_snippets": "Capable of providing informed consent",
                    "criterion": "informed consent capability",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to comply with study procedures",
                    "criterion": "willingness to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Total bilirubin ≤ 1.5X the ULN; ≤ 2x ULN for patients with Gilbert's disease",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤ 1.5X the ULN; ≤ 2x ULN for patients with Gilbert's disease",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (for patients with Gilbert's disease)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Surgery planned as part of definitive local therapy",
            "criterions": [
                {
                    "exact_snippets": "Surgery planned as part of definitive local therapy",
                    "criterion": "surgery",
                    "requirements": [
                        {
                            "requirement_type": "planned",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "purpose",
                            "expected_value": "definitive local therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Biopsy-proven ER+ DCIS",
            "criterions": [
                {
                    "exact_snippets": "Biopsy-proven",
                    "criterion": "diagnosis by biopsy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ER+",
                    "criterion": "estrogen receptor status",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "DCIS",
                    "criterion": "ductal carcinoma in situ",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women presenting with concurrent bilateral DCIS are eligible only if both the right and left DCIS lesions are ER+, and tissue from both sides will be analyzed and must meet the criteria below",
            "criterions": [
                {
                    "exact_snippets": "Women presenting with concurrent bilateral DCIS",
                    "criterion": "concurrent bilateral DCIS",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "both the right and left DCIS lesions are ER+",
                    "criterion": "ER status of DCIS lesions",
                    "requirements": [
                        {
                            "requirement_type": "estrogen receptor status",
                            "expected_value": "positive for both right and left DCIS lesions"
                        }
                    ]
                },
                {
                    "exact_snippets": "tissue from both sides will be analyzed",
                    "criterion": "tissue from both sides",
                    "requirements": [
                        {
                            "requirement_type": "analysis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "tissue from both sides ... must meet the criteria below",
                    "criterion": "tissue from both sides",
                    "requirements": [
                        {
                            "requirement_type": "meets additional criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. AST and ALT ≤ 2.5X ULN",
            "criterions": [
                {
                    "exact_snippets": "AST and ALT ≤ 2.5X ULN",
                    "criterion": "AST (aspartate aminotransferase) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "AST and ALT ≤ 2.5X ULN",
                    "criterion": "ALT (alanine aminotransferase) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. INR/PT/aPTT ≤ 1.5X ULN or within the therapeutic range if on anti-coagulation",
            "criterions": [
                {
                    "exact_snippets": "INR/PT/aPTT ≤ 1.5X ULN",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "INR/PT/aPTT ≤ 1.5X ULN",
                    "criterion": "PT",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "INR/PT/aPTT ≤ 1.5X ULN",
                    "criterion": "aPTT",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within the therapeutic range if on anti-coagulation",
                    "criterion": "coagulation parameters (INR/PT/aPTT) for patients on anti-coagulation",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within the therapeutic range"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. DCIS must be ≥ 1cm based on the extent of calcifications on mammogram, the presence of a mass on ultrasound or enhancement on MRI OR DCIS ≥ 5mm on one single core by pathologic evaluation OR DCIS < 5mm if identified in ≥ 2 cores",
            "criterions": [
                {
                    "exact_snippets": "DCIS must be ≥ 1cm based on the extent of calcifications on mammogram",
                    "criterion": "DCIS size (mammogram calcifications)",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "extent of calcifications on mammogram"
                        }
                    ]
                },
                {
                    "exact_snippets": "the presence of a mass on ultrasound",
                    "criterion": "DCIS presence (ultrasound mass)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "mass on ultrasound"
                        }
                    ]
                },
                {
                    "exact_snippets": "enhancement on MRI",
                    "criterion": "DCIS presence (MRI enhancement)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "enhancement on MRI"
                        }
                    ]
                },
                {
                    "exact_snippets": "DCIS ≥ 5mm on one single core by pathologic evaluation",
                    "criterion": "DCIS size (single core, pathology)",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "one single core by pathologic evaluation"
                        }
                    ]
                },
                {
                    "exact_snippets": "DCIS < 5mm if identified in ≥ 2 cores",
                    "criterion": "DCIS size and distribution (multiple cores, pathology)",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "number of cores",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "cores"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "pathologic evaluation"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "4. Recurrent ipsilateral DCIS",
            "criterions": [
                {
                    "exact_snippets": "Recurrent ipsilateral DCIS",
                    "criterion": "ipsilateral DCIS",
                    "requirements": [
                        {
                            "requirement_type": "recurrence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. History of immune deficiency",
            "criterions": [
                {
                    "exact_snippets": "History of immune deficiency",
                    "criterion": "immune deficiency",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Received a live vaccine within 30 days of the first dose of treatment",
            "criterions": [
                {
                    "exact_snippets": "Received a live vaccine within 30 days of the first dose of treatment",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Invasive breast cancer > 1mm on pathologic evaluation",
            "criterions": [
                {
                    "exact_snippets": "Invasive breast cancer > 1mm on pathologic evaluation",
                    "criterion": "invasive breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathologic evaluation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Current hormone replacement therapy, selective estrogen receptor modulator therapy, or aromatase inhibitor therapy--if yes, wash out of 30 days must occur prior to baseline biopsy for the study",
            "criterions": [
                {
                    "exact_snippets": "Current hormone replacement therapy ... if yes, wash out of 30 days must occur prior to baseline biopsy",
                    "criterion": "hormone replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Current ... selective estrogen receptor modulator therapy ... if yes, wash out of 30 days must occur prior to baseline biopsy",
                    "criterion": "selective estrogen receptor modulator therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Current ... aromatase inhibitor therapy ... if yes, wash out of 30 days must occur prior to baseline biopsy",
                    "criterion": "aromatase inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. History of allergies to any component of the MUC1 vaccine or HiltonolR adjuvant",
            "criterions": [
                {
                    "exact_snippets": "History of allergies to any component of the MUC1 vaccine",
                    "criterion": "allergies to MUC1 vaccine components",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of allergies to any component of the ... HiltonolR adjuvant",
                    "criterion": "allergies to HiltonolR adjuvant components",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Known active hepatitis B (hepatitis B surface antigen-reactive) or hepatitis C (hepatitis C virus RNA positive). Patients who are hepatitis B core antibody positive without hepatitis B surface antigen reactivity are eligible. Patients who have antibody for hepatitis C are eligible only if hepatitis C RNA is negative by PCR.",
            "criterions": [
                {
                    "exact_snippets": "Known active hepatitis B (hepatitis B surface antigen-reactive)",
                    "criterion": "active hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B surface antigen-reactive",
                    "criterion": "hepatitis B surface antigen",
                    "requirements": [
                        {
                            "requirement_type": "reactivity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B core antibody positive without hepatitis B surface antigen reactivity are eligible",
                    "criterion": "hepatitis B core antibody",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B core antibody positive without hepatitis B surface antigen reactivity are eligible",
                    "criterion": "hepatitis B surface antigen",
                    "requirements": [
                        {
                            "requirement_type": "reactivity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C (hepatitis C virus RNA positive)",
                    "criterion": "hepatitis C virus RNA",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have antibody for hepatitis C are eligible only if hepatitis C RNA is negative by PCR",
                    "criterion": "hepatitis C antibody",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have antibody for hepatitis C are eligible only if hepatitis C RNA is negative by PCR",
                    "criterion": "hepatitis C virus RNA",
                    "requirements": [
                        {
                            "requirement_type": "negativity by PCR",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Active infection requiring systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring systemic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Current Immunomodulator therapy (includes anti-CD20 antibodies)",
            "criterions": [
                {
                    "exact_snippets": "Current Immunomodulator therapy",
                    "criterion": "immunomodulator therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "(includes anti-CD20 antibodies)",
                    "criterion": "anti-CD20 antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Participation on any investigational vaccine, drug, or device trial within the last 30 days",
            "criterions": [
                {
                    "exact_snippets": "Participation on any investigational vaccine, drug, or device trial within the last 30 days",
                    "criterion": "participation in investigational trial",
                    "requirements": [
                        {
                            "requirement_type": "type of trial",
                            "expected_value": [
                                "vaccine",
                                "drug",
                                "device"
                            ]
                        },
                        {
                            "requirement_type": "time since participation",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Known history of HIV (presence of HIV antibodies for HIV 1 and HIV 2)",
            "criterions": [
                {
                    "exact_snippets": "Known history of HIV (presence of HIV antibodies for HIV 1 and HIV 2)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of HIV antibodies for HIV 1 and HIV 2",
                    "criterion": "HIV antibodies (HIV 1 and HIV 2)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Second malignancy within the last 5 years (definitively treated superficial non-melanoma skin cancer, melanoma in situ, cervical carcinoma in situ allowed)",
            "criterions": [
                {
                    "exact_snippets": "Second malignancy within the last 5 years",
                    "criterion": "second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis or treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. History of autoimmune disease requiring systemic immunosuppression, or active autoimmune disease. Replacement therapy with thyroxine, insulin, and physiologic corticosteroids for adrenal or pituitary insufficiency is acceptable.",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune disease requiring systemic immunosuppression",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic immunosuppression"
                        }
                    ]
                },
                {
                    "exact_snippets": "active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Current steroid therapy (doses for physiologic replacement in adrenal dysfunction or for contrast allergy pre-medication for contrast allergy or similar indication allowed, topical, ocular and intranasal steroids allowed)",
            "criterions": [
                {
                    "exact_snippets": "Current steroid therapy",
                    "criterion": "steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "doses for physiologic replacement in adrenal dysfunction ... allowed",
                    "criterion": "steroid therapy for adrenal dysfunction (physiologic replacement)",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for contrast allergy pre-medication ... allowed",
                    "criterion": "steroid therapy for contrast allergy pre-medication",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "topical, ocular and intranasal steroids allowed",
                    "criterion": "topical, ocular and intranasal steroid use",
                    "requirements": [
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Any medical or psychiatric condition, substance abuse disorder, medical therapy, or laboratory abnormality that might interfere with the patient's participation for the full duration of the study or compliance with the requirements of the study",
            "criterions": [
                {
                    "exact_snippets": "Any medical or psychiatric condition ... that might interfere with the patient's participation for the full duration of the study or compliance with the requirements of the study",
                    "criterion": "medical condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or compliance",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any ... psychiatric condition ... that might interfere with the patient's participation for the full duration of the study or compliance with the requirements of the study",
                    "criterion": "psychiatric condition",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or compliance",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any ... substance abuse disorder ... that might interfere with the patient's participation for the full duration of the study or compliance with the requirements of the study",
                    "criterion": "substance abuse disorder",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or compliance",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any ... medical therapy ... that might interfere with the patient's participation for the full duration of the study or compliance with the requirements of the study",
                    "criterion": "medical therapy",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or compliance",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any ... laboratory abnormality ... that might interfere with the patient's participation for the full duration of the study or compliance with the requirements of the study",
                    "criterion": "laboratory abnormality",
                    "requirements": [
                        {
                            "requirement_type": "potential to interfere with study participation or compliance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}